Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Ligand Pharmaceuticals Incorporated

LGND

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Ligand Pharmaceuticals Incorporated. A complete text table follows the diagram.

Ligand Partnered Medicines Revenue Flow

Partnered medicines and royalty economics drive a biotech licensing platform.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0000886163-26-000034
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Ligand reports $51.722M of total revenues and income, including product and royalty economics from its partnered portfolio.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Ligand Pharmaceuticals Incorporated revenue	1	$51.7M	$51.722M reported quarterly revenue
Partnered medicines and royalties	2	$51.7M	Reported total revenues and income

Financial flows · Millions of USD
From	To	Value
Ligand Pharmaceuticals Incorporated revenue	Partnered medicines and royalties	$51.7M